Telesis Bio Company Executives

TBIO Stock  USD 0.05  0  2.00%   
Telesis Bio employs about 101 people. The company is managed by 10 executives with a total tenure of roughly 236 years, averaging almost 23.0 years of service per executive, having 10.1 employees per reported executive. Analysis of Telesis Bio's management performance can provide insight into the firm performance.
Eric Esser  CEO
CEO, President
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Telesis Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

Telesis Bio Management Team Effectiveness

The company has return on total asset (ROA) of (0.2652) % which means that it has lost $0.2652 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4784) %, meaning that it created substantial loss on money invested by shareholders. Telesis Bio's management efficiency ratios could be used to measure how well Telesis Bio manages its routine affairs as well as how well it operates its assets and liabilities.
Telesis Bio maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.
Some institutional investors establish a significant position in pink sheets such as Telesis Bio in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Telesis Bio, and when they decide to sell, the pink sheet will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Telesis Bio Workforce Comparison

Telesis Bio is currently regarded as top stock in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 1,732. Telesis Bio holds roughly 101 in number of employees claiming about 6% of equities under Health Care industry.
The company has Profit Margin (PM) of (2.53) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (6.76) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $6.76.

Telesis Bio Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Telesis Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Telesis Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Telesis Bio insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Telesis Bio Notable Stakeholders

A Telesis Bio stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Telesis Bio often face trade-offs trying to please all of them. Telesis Bio's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Telesis Bio's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Eric EsserCEO, PresidentProfile
Richard LepkeDirector RelationsProfile
Dr MBAFounder DirectorProfile
Decky MBASenior DevelopmentProfile
Laura MBAVice CultureProfile
Jen CarrollVice RelationsProfile
Laurence WardenSenior InstrumentationProfile
William KullbackChief OfficerProfile
Daniel GibsonChief OfficerProfile
Robert CutlerChief OfficerProfile
String symbol = request.getParameter("s");

About Telesis Bio Management Performance

The success or failure of an entity such as Telesis Bio often depends on how effective the management is. Telesis Bio management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Telesis management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Telesis management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Translate Bio, Inc., a clinical-stage messenger RNA therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company was founded in 2011 and is headquartered in Lexington, Massachusetts. Translate Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 122 people.

Telesis Bio Workforce Analysis

Traditionally, organizations such as Telesis Bio use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Telesis Bio within its industry.

Telesis Bio Manpower Efficiency

Return on Telesis Bio Manpower

Revenue Per Employee272.4K
Revenue Per Executive2.8M
Net Loss Per Employee472.5K
Net Loss Per Executive4.8M
Working Capital Per Employee219.5K
Working Capital Per Executive2.2M

Other Information on Investing in Telesis Pink Sheet

Telesis Bio financial ratios help investors to determine whether Telesis Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Telesis with respect to the benefits of owning Telesis Bio security.